Milestone Pharmaceuticals MIST
$ 1.84
-1.08%
Quarterly report 2024-Q3
added 11-12-2024
Milestone Pharmaceuticals Balance Sheet 2011-2024 | MIST
Annual Balance Sheet Milestone Pharmaceuticals
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
36.6 M | -5.14 M | -113 M | -71.4 M | -119 M | -85.9 M | -10.9 M | - | - | - | - | - | - |
Long Term Debt |
49.8 M | 2 M | 474 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
546 K | 495 K | 224 K | 245 K | 330 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 696 K | 184 K | 139 M | 59.1 M | - | - | - | - | - | - |
Total Current Liabilities |
7.23 M | 6.14 M | 6.78 M | 6.16 M | 8.33 M | 4.53 M | - | - | - | - | - | - | - |
Total Liabilities |
58.5 M | 8.14 M | 7.25 M | 6.86 M | 8.51 M | 143 M | 60.7 M | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-326 M | -266 M | -208 M | -163 M | -113 M | -58.3 M | -35.1 M | - | - | - | - | - | - |
Total Assets |
75.2 M | 74.5 M | 120 M | 150 M | 123 M | 88.1 M | 27.6 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
13.8 M | 7.64 M | 114 M | 72.3 M | 120 M | 85.9 M | 10.9 M | - | - | - | - | - | - |
Book Value |
16.8 M | 66.3 M | 113 M | 143 M | 115 M | -55.2 M | -33.1 M | - | - | - | - | - | - |
Total Shareholders Equity |
16.8 M | 66.3 M | 113 M | 143 M | 115 M | 83.5 M | 26 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Milestone Pharmaceuticals
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
52.4 M | 51.5 M | 50.6 M | 49.8 M | 48.9 M | 48.1 M | 47.3 M | 2 M | 2.09 M | 384 K | 433 K | 474 K | 512 K | 573 K | 635 K | 696 K | 696 K | 696 K | 696 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
58.7 M | 57.3 M | 56.1 M | 58.5 M | 58.6 M | 56.6 M | 57.1 M | 8.14 M | 8.61 M | 4.64 M | 5.04 M | 7.25 M | 6.36 M | 5.9 M | 6.45 M | 6.86 M | 6.86 M | 6.86 M | 6.86 M | 8.51 M | 8.51 M | 8.51 M | 8.51 M | 4.53 M | 4.53 M | 4.53 M | 4.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-355 M | -346 M | -336 M | -326 M | -312 M | -297 M | -281 M | -266 M | -252 M | -237 M | -220 M | -206 M | -189 M | -175 M | -176 M | -163 M | -163 M | -163 M | -163 M | -113 M | -113 M | -113 M | -113 M | -58.3 M | -58.3 M | -58.3 M | -58.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
82.7 M | 89.2 M | 96 M | 75.2 M | 87.1 M | 97 M | 111 M | 74.5 M | 85.8 M | 91.3 M | 106 M | 120 M | 134 M | 145 M | 138 M | 150 M | 150 M | 150 M | 150 M | 123 M | 123 M | 123 M | 123 M | 88.1 M | 88.1 M | 88.1 M | 88.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
12.8 M | 13.3 M | 10.1 M | 13.8 M | 9.88 M | 32.6 M | 74 M | 7.64 M | 37.3 M | 63.2 M | 92.2 M | 114 M | 111 M | 97.8 M | 71.9 M | 72.3 M | 72.3 M | 72.3 M | 72.3 M | 120 M | 120 M | 120 M | 120 M | 85.9 M | 85.9 M | 85.9 M | 85.9 M | 10.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
24 M | 32 M | 39.9 M | 16.8 M | 28.5 M | 40.4 M | 53.9 M | 66.3 M | 77.2 M | 86.7 M | 101 M | 113 M | 127 M | 140 M | 132 M | 143 M | 143 M | 143 M | 143 M | 115 M | 115 M | 115 M | 115 M | 83.5 M | 83.5 M | 83.5 M | 83.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
24 M | 32 M | 39.9 M | 16.8 M | 28.5 M | 40.4 M | 53.9 M | 66.3 M | 77.2 M | 86.7 M | 101 M | 113 M | 127 M | 140 M | 132 M | 143 M | 143 M | 143 M | 143 M | 115 M | 115 M | 115 M | 115 M | 83.5 M | -55.2 M | -55.2 M | -55.2 M | 26 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency